New drug combo shows promise for controlling recurrent uterine cancer
NCT ID NCT01068249
First seen Nov 18, 2025 · Last updated Apr 30, 2026 · Updated 17 times
Summary
This study tested whether a combination of two drugs, letrozole and everolimus, can help control advanced or recurrent endometrial cancer. 42 participants with progressive or recurrent disease were enrolled. The goal was to see if the tumors shrank or stopped growing, and to check the safety of the combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Morristown Memorial Hospital, Women's Cancer Center
Morristown, New Jersey, 07962, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.